Santen Pharmaceutical Co. Ltd.
SNPHY | OTC
$11.23
+$0.45 (+4.17%)
At close: Oct 30, 2026, 3:15 PM ET
$11.23
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:00 PM ET
Fiscal Year Period Ending | FY 2026 Mar 31, 2026 | FY 2025 Mar 31, 2025 | FY 2024 Mar 31, 2024 | FY 2023 Mar 31, 2023 | FY 2022 Mar 31, 2022 | FY 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|
Revenue | 291.62B | 300B | 301.97B | 279.04B | 266.26B | 249.61B |
Cost of Revenue | 130.65B | 136.8B | 138.09B | 122.47B | 119.41B | 108.87B |
Gross Profit | 160.97B | 163.21B | 163.88B | 156.57B | 146.85B | 140.73B |
Operating Income | 45.22B | 56.23B | 51.9B | 32.02B | 35.98B | 37.07B |
Interest Income | 1.64B | 1.05B | 619M | 469M | 402M | 282M |
Pretax Income | 47.44B | 47.48B | 29.87B | -5.8B | 35.62B | 11.69B |
Net Income | 37.37B | 36.26B | 26.64B | -14.95B | 27.22B | 9.31B |
Selling & General & Admin | 89.57B | 83.51B | 87.27B | 96.26B | 84.5B | 79.55B |
Research & Development | 26.19B | 23.47B | 24.7B | 28.3B | 26.38B | 24.11B |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 115.76B | 106.98B | 111.97B | 124.55B | 110.88B | 103.67B |
Interest Expense | 1.99B | 1.08B | 831M | 486M | 250M | 172M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 246.41B | 243.77B | 250.06B | 247.02B | 230.28B | 212.54B |
Income Tax Expense | 9.88B | 11.63B | 3.17B | 9.18B | 8.43B | 2.56B |
Shares Outstanding (Basic) | 327.62M | 348.61M | 366.89M | 387.42M | 399.78M | 399.46M |
Shares Outstanding (Diluted) | 328.37M | 349.69M | 368.14M | 387.42M | 400.46M | 400.39M |
EPS (Basic) | 114.04 | 103.98 | 72.59 | -38.60 | 68.07 | 23.30 |
EPS (Diluted) | 113.80 | 103.68 | 72.37 | -38.60 | 67.97 | 23.26 |
EBITDA | 67.79B | 66.51B | 48.88B | 11.94B | 52.92B | 54.99B |
EBIT | 49.44B | 48.56B | 30.71B | -5.31B | 35.87B | 37.07B |
Depreciation & Amortization | 18.36B | 17.95B | 18.18B | 17.25B | 17.06B | 17.92B |
Add to Watchlist
Select watchlists to add or remove SNPHY